Ferritin-based nanovectors that engage TfR1 can traverse the blood–brain barrier and, via intranasal routes, concentrate cytotoxic payloads within high-TfR1 gliomas, improving survival in vivo [60]. This evidence concerns the gene TFRC and central nervous system cancer.